Echo IQ Taps Mayo Clinic to Validate AI in Cardio-Oncology Market

SYDNEY, Australia – June 12, 2026 – In a significant move that underscores the growing convergence of artificial intelligence and specialized medicine, Australian med-tech firm Echo IQ Limited (ASX: EIQ) has announced a research collaboration with the world-renowned Mayo Clinic. The partnership aims to evaluate Echo IQ's AI platform for its ability to predict heart failure risk in cancer patients, a critical step toward commercializing its technology in the rapidly expanding cardio-oncology field.

This collaboration isn't just another research project; it represents a crucial milestone on the path from prototype to profit. By aligning with a global leader in healthcare, Echo IQ is seeking the clinical validation necessary to unlock a market born from one of modern medicine's greatest triumphs: the increasing survival rate of cancer patients.

The Growing Crisis of Cardiotoxicity

As cancer treatments become more effective, a new challenge has emerged from the shadows of survival: cardiotoxicity. The very therapies that save lives can inflict long-term damage on the heart, a grim paradox that has given rise to the specialized field of cardio-oncology. With over 20 million new cancer cases diagnosed globally each year, the number of patients at risk is substantial.

Research indicates that cardiotoxicity is far from a rare complication. A systematic review found that approximately 8.3% of cancer patients undergoing chemotherapy experience treatment-related cardiovascular events, with some studies reporting incidences as high as 43%. This damage, which can manifest as heart failure, arrhythmias, or coronary artery disease, carries a heavy toll, increasing a patient's mortality risk by a staggering 3.5-fold. The current gold standard for diagnosis, an endomyocardial biopsy, is invasive and rarely used, leaving clinicians to rely on imaging and biomarkers that lack consensus on timing and application.

This clinical gap creates a significant market opportunity. The AI in cardiology market, valued at over $2 billion in 2025, is projected to surge to over $14 billion within the next decade. Echo IQ is positioning itself to capture a piece of this market by providing a tool that addresses the unmet need for early and accurate risk stratification, potentially preventing irreversible heart damage before clinical symptoms even appear.

A Strategic Alliance for Validation and Expansion

For any technology company, particularly in the highly regulated medical device space, securing a partnership with an institution of Mayo Clinic's caliber is a powerful form of currency. This collaboration provides Echo IQ with more than just data; it offers profound scientific and commercial validation. Mayo Clinic is not merely a participant but a leader in AI-driven cardiology, with its own dedicated teams developing and validating algorithms for early risk prediction. Their decision to collaborate with Echo IQ signals a recognition of the external platform's potential.

The study, titled "Evaluation of Cardiotoxicity in Patients Receiving Cancer Therapy and Risk Stratification," will be conducted at Mayo Clinic Arizona under the direction of Chadi Ayoub, M.B.B.S., Ph.D. It represents a strategic expansion for Echo IQ, whose core AI platform, EchoSolv, already holds FDA 510(k) clearance for detecting severe Aortic Stenosis. While that clearance was a critical first step, the company has its sights on a much larger prize: heart failure, a market estimated at US$70 billion annually.

Echo IQ has a separate FDA application for heart failure currently under review, supported by a validation study that demonstrated a 99.5% sensitivity in identifying patients with the condition. This new cardio-oncology study with Mayo Clinic runs on a parallel track, aiming to prove the platform's utility in a specific, high-need patient population and paving the way for another potential market entry.

How Echo IQ's AI Aims to Reshape Patient Care

The research will assess whether Echo IQ's AI model can generate predictive risk scores for heart failure using routinely acquired echocardiographic data—the standard ultrasound images of the heart. The process will take place within a secure environment, using de-identified data to train and test the algorithm's predictive power. The goal is to provide clinicians with an actionable risk score at the point of care, enabling them to make more informed decisions.

"This collaboration with Mayo Clinic represents an important opportunity to evaluate the Company's cardiac AI platform in a high-need clinical population, where earlier identification of cardiovascular risk may inform clinical decision making," said Echo IQ's Chief Executive Officer, Mr. Dustin Haines.

For patients, such a tool could be transformative. Early detection allows for timely interventions, such as prescribing cardioprotective medications or adjusting cancer therapy to balance oncologic efficacy with cardiovascular safety. It helps address the hidden cost of cancer survival, improving long-term quality of life. For clinicians, an automated, AI-driven analysis promises to streamline workflows and provide an objective measure to supplement their clinical judgment, a vital advantage in a field where guidelines can be complex and evidence is still evolving.

Navigating the Path from Prototype to Profit

Echo IQ's journey exemplifies the multi-pronged strategy required to commercialize novel medical technology. The company has already achieved its first major regulatory win with FDA clearance for aortic stenosis. It is actively pursuing a second, much larger indication with its pending heart failure application. Now, through the Mayo Clinic collaboration, it is laying the groundwork for a third pillar in cardio-oncology. The parties intend to co-author a manuscript for peer-reviewed publication upon the study's completion, expected in the first half of 2027, which would further cement the technology's credibility.

This steady progression has not gone unnoticed by the market, with the company's recent inclusion in the S&P/ASX All Ordinaries Index reflecting its growth. As Mr. Haines noted, "As cancer survival rates continue to improve, healthcare systems are increasingly focused on managing the long-term cardiac consequences of cancer therapy." By developing a tool to address this specific pain point, Echo IQ is demonstrating a keen understanding of where clinical need and commercial opportunity intersect, a crucial insight for any company navigating the long road from prototype to profit.